[go: up one dir, main page]

PE20140626A1 - Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona - Google Patents

Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona

Info

Publication number
PE20140626A1
PE20140626A1 PE2013002083A PE2013002083A PE20140626A1 PE 20140626 A1 PE20140626 A1 PE 20140626A1 PE 2013002083 A PE2013002083 A PE 2013002083A PE 2013002083 A PE2013002083 A PE 2013002083A PE 20140626 A1 PE20140626 A1 PE 20140626A1
Authority
PE
Peru
Prior art keywords
bis
benzodiazepinone
fluoroalkyl
compounds
benzodiazepin
Prior art date
Application number
PE2013002083A
Other languages
English (en)
Inventor
Claude Quesnelle
Soong-Hoon Kim
Francis Lee
Ashvinikumar Gaval
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45894701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140626(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20140626A1 publication Critical patent/PE20140626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE BIS(FLUOROALQUIL)-1,4-BENZODIAZEPINONA DE FORMULA (I) DONDE R1 ES -CH2CF3 O -CH2CH2CF3; R2 ES -CH2CF3, -CH2CH2CF3 O -CH2CH2CH2CF3; R3 ES H O -CH3; Ra ES F, Cl, -CN, ENTRE OTROS; z ES DE 0 A 2. SON COMPUESTOS PREFERIDOS: (2R,3S)-N-((3S)-1-METIL-2-OXO-5-FENIL-2,3-DIHIDRO-1H-1,4-BENZODIAZEPIN-3-IL)-2,3-BIS(3,3,3-TRIFLUOROPROPIL)SUCCINAMIDA; (2R,3S)-N-((3S)-2-OXO-5-FENIL-2,3-DIHIDRO-1H-1,4-BENZODIAZEPIN-3-IL)-2,3-BIS(3,3,3-TRIFLUOROPROPIL)SUCCINAMIDA; (2R,3S)-N-((3S)-1-METIL-2-OXO-5-FENIL-2,3-DIHIDRO-1H-1,4-BENZODIAZEPIN-3-IL)-2-(2,2,2-TRIFLUOROETIL)-3-(3,3,3-TRIFLUOROPROPIL)SUCCINAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMA CRISTALINA Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE NOTCH SIENDO UTILES EN EL TRATAMIENTO DE CANCER
PE2013002083A 2011-03-22 2012-03-22 Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona PE20140626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161466238P 2011-03-22 2011-03-22

Publications (1)

Publication Number Publication Date
PE20140626A1 true PE20140626A1 (es) 2014-05-30

Family

ID=45894701

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002083A PE20140626A1 (es) 2011-03-22 2012-03-22 Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona

Country Status (32)

Country Link
US (2) US8629136B2 (es)
EP (1) EP2688873B1 (es)
JP (1) JP5873923B2 (es)
KR (1) KR101948347B1 (es)
CN (1) CN103717576B (es)
AR (2) AR085471A1 (es)
AU (1) AU2012230904B2 (es)
BR (1) BR112013024059B1 (es)
CA (1) CA2830902C (es)
CL (1) CL2013002690A1 (es)
CO (1) CO6771446A2 (es)
CY (1) CY1116423T1 (es)
DK (1) DK2688873T3 (es)
EA (1) EA022530B1 (es)
ES (1) ES2534080T3 (es)
HR (1) HRP20150273T1 (es)
IL (1) IL228534A (es)
MA (1) MA35036B1 (es)
MX (1) MX2013010420A (es)
MY (1) MY161233A (es)
PE (1) PE20140626A1 (es)
PH (1) PH12013501738B1 (es)
PL (1) PL2688873T3 (es)
PT (1) PT2688873E (es)
RS (1) RS53843B1 (es)
SG (1) SG193555A1 (es)
SI (1) SI2688873T1 (es)
SM (1) SMT201500091B (es)
TN (1) TN2013000372A1 (es)
TW (1) TWI530489B (es)
UY (1) UY33961A (es)
WO (1) WO2012129353A1 (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
JP2015529251A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｎｏｔｃｈ阻害剤としての三環系複素環式化合物
JP2015529250A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキルジベンゾジアゼピノン化合物
JP2015534554A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物
CN104854097A (zh) * 2012-09-21 2015-08-19 百时美施贵宝公司 N-取代的二(氟烷基)-1,4-苯并二氮杂*酮化合物
WO2014047397A1 (en) * 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
TWI614238B (zh) * 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
CN104968648A (zh) * 2012-09-21 2015-10-07 百时美施贵宝公司 1,4-苯并二氮杂*酮化合物的前药
JP2015529252A (ja) 2012-09-21 2015-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ フルオロアルキル−１，４−ベンゾジアゼピノン化合物
CA2889638A1 (en) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a dll4 antagonist
US9492469B2 (en) 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
WO2015013579A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
CN103435562B (zh) * 2013-08-26 2016-02-24 华东理工大学 6-取代苯并二氮卓-2,4-二酮类化合物及其用途
CN104356082B (zh) * 2014-10-31 2016-07-13 厦门大学 一类取代杂环衍生物及其制备方法
CN104352488B (zh) * 2014-10-31 2016-08-31 厦门大学 一类取代杂环衍生物在制备治疗疼痛药物中的应用
DK3212233T3 (da) 2014-10-31 2020-07-27 Oncomed Pharm Inc Kombinationsterapi til behandling af sygdom
WO2016066115A1 (zh) * 2014-10-31 2016-05-06 厦门大学 取代杂环衍生物、其制备方法和用途
CN104892532B (zh) * 2015-05-20 2017-09-08 成都理工大学 手性3‑取代1,3,4,5‑四氢‑1,4‑苯二氮*‑2‑酮的合成工艺
KR102667914B1 (ko) 2015-07-22 2024-05-21 이난타 파마슈티칼스, 인코포레이티드 Rsv 저해제로서의 벤조다이아제핀 유도체
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
CN108699077B (zh) 2016-01-15 2021-03-02 英安塔制药有限公司 作为rsv抑制剂的杂环化合物
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
NZ756805A (en) 2017-02-16 2025-10-31 Enanta Pharm Inc Processes for the preparation of benzodiazepine derivatives
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US10752598B2 (en) 2017-06-07 2020-08-25 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as RSV inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
ES2817910T3 (es) * 2017-08-04 2021-04-08 Alzheimur 2012 S L Uso de un anticuerpo antipresenilina para la prevención y/o tratamiento del cáncer
US10881666B2 (en) 2017-09-29 2021-01-05 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
CN111343990B (zh) 2017-11-13 2023-08-04 英安塔制药有限公司 苯并二氮杂䓬-2-酮和苯并氮杂䓬-2-酮衍生物的拆分方法
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
KR20210005714A (ko) 2018-05-06 2021-01-14 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
US20210379079A1 (en) * 2018-05-06 2021-12-09 Ayala Pharmaceuticals Inc. Compositions comprising cd20 inhibitors and bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
AU2019271044A1 (en) * 2018-05-15 2021-01-14 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-l,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
US20210220372A1 (en) * 2018-05-15 2021-07-22 Bristol-Myers Squibb Company Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof
AU2019275284A1 (en) * 2018-05-24 2021-01-14 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
IL317554A (en) 2018-06-01 2025-02-01 Novartis Ag Anti-BCMA binding molecules and their uses
KR20210138684A (ko) 2019-03-18 2021-11-19 이난타 파마슈티칼스, 인코포레이티드 Rsv 억제제로서의 벤조디아제핀 유도체
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
CN113939297A (zh) * 2019-05-15 2022-01-14 艾雅拉制药公司 用于治疗Notch活化的乳腺癌的双氟烷基-1,4-苯并二氮杂卓酮化合物
EP3986569A1 (en) 2019-06-24 2022-04-27 Novartis AG Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US11572367B2 (en) 2019-10-04 2023-02-07 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
MX2023002612A (es) * 2020-09-03 2023-05-16 Bristol Myers Squibb Co Polimorfos de compuestos de bis(fluoroalquilo)-1,4-benzodiazepinon a y usos de los mismos.
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US20240041884A1 (en) 2020-12-07 2024-02-08 Cellestia Biotech Ag Pharmaceutical Combinations for Treating Cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
AU2022227674A1 (en) 2021-02-26 2023-09-21 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
WO2023079132A1 (en) 2021-11-08 2023-05-11 Cellestia Biotech Ag Pharmaceutical combinations for treating cancer
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
US12162857B2 (en) 2022-04-27 2024-12-10 Enanta Pharmaceuticals, Inc. Antiviral compounds
WO2024145306A1 (en) * 2022-12-28 2024-07-04 Ayala Pharmaceuticals Inc. Intermediate salt for the preparation of bis(fluoroalkyl) benzodiazepinone compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324726A (en) 1989-12-18 1994-06-28 Merck & Co., Inc. Benzodiazepine analogs
US5852010A (en) 1996-04-03 1998-12-22 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507587A (ja) * 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシルタンパク質トランスフェラーゼ阻害剤
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
HRP990246A2 (en) 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
CA2346099A1 (en) 1998-11-12 2000-05-18 Dupont Pharmaceuticals Company Use of radioligands to screen inhibitors of amyloid-beta peptide production
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
AU778005B2 (en) * 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
DE60042425D1 (de) 1999-04-30 2009-07-30 Univ Michigan Verwendung von Benzodiazepinen zur Behandlung von autoimmunischen Krankheiten, Entzündungen, Neoplasien, viralen Infektionen und Atherosklerosis
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
CA2387493A1 (en) 1999-10-08 2001-04-19 Lorin Andrew Thompson Amino lactam sulfonamides as inhibitors of a.beta. protein production
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP2003520266A (ja) 2000-01-24 2003-07-02 メルク シャープ エンド ドーム リミテッド γ−セクレターゼ阻害薬
AU2001239791A1 (en) 2000-02-17 2001-08-27 Du Pont Pharmaceuticals Company Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
WO2001074796A1 (en) 2000-03-31 2001-10-11 Bristol-Myers Squibb Pharma Company SUCCINOYLAMINO HETEROCYCLES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
MXPA02009729A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
IL151576A0 (en) 2000-04-03 2003-04-10 Bristol Myers Squibb Pharma Co Cyclic lactams as inhibitors of a-beta protein production
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
WO2001077086A1 (en) 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
US6878363B2 (en) 2000-05-17 2005-04-12 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
GB0012671D0 (en) 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
EP1268450A1 (en) 2000-06-01 2003-01-02 Bristol-Myers Squibb Pharma Company Lactams substituted by cyclic succinates as inhibitors of a-beta protein production
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
WO2004026843A1 (en) 2002-09-20 2004-04-01 Arrow Therapeutics Limited Benzodiazepine derivatives and pharmaceutical compositions containing them
MXPA05008172A (es) 2003-02-04 2005-10-05 Hoffmann La Roche Derivados de malonamida como inhibidores gamma-secretasa.
GB0312365D0 (en) 2003-05-30 2003-07-02 Univ Aston Novel 3-substituted-1, 4-benzodiazepines
KR20070087233A (ko) 2003-09-09 2007-08-27 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
EP1795198A1 (en) 2005-12-09 2007-06-13 Hubrecht Laboratorium Treatment of Barret's esophagus
EP2198863A1 (en) 2006-02-27 2010-06-23 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
KR101169628B1 (ko) 2006-03-27 2012-07-30 에프. 호프만-라 로슈 아게 감마 세크레테아제 저해제로서의 말론아미드 유도체
MX2009002538A (es) 2006-09-20 2009-03-20 Hoffmann La Roche Derivados de 4-oxo-2,3,4,5-tetrahidro-benzo[b][1,4]diazepina.
AU2008287124B2 (en) 2007-08-14 2013-06-06 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
CN101909633B (zh) 2008-01-11 2012-05-30 霍夫曼-拉罗奇有限公司 γ-分泌酶抑制剂用于治疗癌症的应用
US8637493B2 (en) 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma
US20120225860A1 (en) 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor

Also Published As

Publication number Publication date
IL228534A0 (en) 2013-12-31
CN103717576A (zh) 2014-04-09
NZ616876A (en) 2014-08-29
CL2013002690A1 (es) 2014-02-14
ES2534080T3 (es) 2015-04-17
RS53843B1 (sr) 2015-08-31
TN2013000372A1 (en) 2015-01-20
EP2688873A1 (en) 2014-01-29
UY33961A (es) 2012-09-28
PT2688873E (pt) 2015-04-14
BR112013024059B1 (pt) 2022-01-25
CA2830902A1 (en) 2012-09-27
JP5873923B2 (ja) 2016-03-01
TW201309656A (zh) 2013-03-01
US20120245151A1 (en) 2012-09-27
MY161233A (en) 2017-04-14
AR129859A2 (es) 2024-10-02
SI2688873T1 (sl) 2015-04-30
PH12013501738B1 (en) 2019-03-13
US8629136B2 (en) 2014-01-14
HK1189218A1 (en) 2014-05-30
CO6771446A2 (es) 2013-10-15
TWI530489B (zh) 2016-04-21
MA35036B1 (fr) 2014-04-03
EA022530B1 (ru) 2016-01-29
EP2688873B1 (en) 2015-01-21
US20140100365A1 (en) 2014-04-10
PL2688873T3 (pl) 2015-06-30
SMT201500091B (it) 2015-05-05
US8822454B2 (en) 2014-09-02
EA201391324A1 (ru) 2014-03-31
AU2012230904A1 (en) 2013-11-07
CN103717576B (zh) 2015-11-25
BR112013024059A2 (pt) 2016-12-06
SG193555A1 (en) 2013-11-29
HRP20150273T1 (hr) 2015-06-19
PH12013501738A1 (en) 2013-10-07
MX2013010420A (es) 2013-10-01
KR101948347B1 (ko) 2019-02-14
KR20140027956A (ko) 2014-03-07
IL228534A (en) 2017-02-28
CY1116423T1 (el) 2017-02-08
WO2012129353A1 (en) 2012-09-27
CA2830902C (en) 2019-10-29
AU2012230904B2 (en) 2016-03-31
DK2688873T3 (en) 2015-04-27
AR085471A1 (es) 2013-10-02
JP2014511840A (ja) 2014-05-19

Similar Documents

Publication Publication Date Title
PE20140626A1 (es) Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20210642A1 (es) Inhibidores de pd-1/pd-l1
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20110368A1 (es) Moduladores de mif
PE20170004A1 (es) Inhibidores de biaril cinasa
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
PE20151274A1 (es) Inhibidores de erk y sus usos
PE20191755A1 (es) Derivados de pirazol como inhibidores de malt 1
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20141824A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20141702A1 (es) Compuestos de carbamato y preparacion y uso de los mismos
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
PE20160874A1 (es) Compuestos quimicos
PE20151072A1 (es) Derivados de (cicloalquilen) bis (1, 3, 4-tiadiazol) como inhibidores de glutaminasa
EA201100037A1 (ru) Органические соединения
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
EA201590748A1 (ru) Противовирусные соединения против rsv
PE20141170A1 (es) Moduladores del transporte nuclear que contienen hidrazida y sus usos
PE20170331A1 (es) Derivados quinolina como inhibidores smo
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2

Legal Events

Date Code Title Description
FG Grant, registration